 CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 29, 2021 GLOBE NEWSWIRE -- Centogene N.V. Nasdaq: CNTG, a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today the publication of results from a ground-breaking global genetic study in the New England Journal of Medicine including findings of a potential treatment of structural birth defects caused by specific gene alterations. 